Ipsen scaling up in the U.S.; Samsung, Biogen submit Remicade biosimilar;

@FierceBiotech: EuroBiotech: Sanofi backs immunotherapy hub, U.K. mulls its own 'breakthrough,' Allergy player banks £20M. Report | Follow @FierceBiotech

@JohnCFierce: Coming up on 500 responses to our survey question: Sustainable bull market or biotech bubble? Let's hear from you. Survey | Follow @JohnCFierce

@DamianFierce: Science RT @NYTArchives: An unlucky kitten is volunteered to test weightlessness inside an F-94C at 25,000 feet, 1958. Picture | Follow @DamianFierce

> Ipsen is planning a major U.S. offensive, staffing up at its Cambridge, MA, hub with hopes of raising its profile in the country. News

> Partners Samsung and Biogen Idec ($BIIB) have submitted European regulatory applications for a biosimilar of Johnson & Johnson's ($JNJ) blockbuster autoimmune treatment Remicade. More

> Chinese CRO WuXi PharmaTech ($WX) is planning to build a U.S. manufacturing operation dedicated to CAR-T treatments and other cancer immunotherapies. Release

Medical Device News

@FierceMedDev: 23andMe launches new therapeutics group with biotech vet taking the reins. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Irish research center wins EU funding to study and develop transdermal delivery methods. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: FDA calls for panel meeting to discuss devices linked to superbug outbreak. Article | Follow @EmilyWFierce

> Zimmer recalls part of Persona--a total knee replacement that helped drive 2014 growth. More

> Medtronic launches U.S. clinical trial of its newest drug-eluting stent. Article

Pharma News

@FiercePharma: Mylan recalls drug after problem uncovered with Indian supplier. FiercePharmaManufacturing article | Follow @FiercePharma

@EricPFierce: DEA says it is not the cause of shortages of scheduled drugs, that it is just misunderstood. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Glaxo to reap $890M as it halves stake in South Africa's Aspen. Story | Follow @CarlyHFierce

> Newly beefed-up Par Pharma files for an IPO. Article

> Cancer Drug Fund has failed, ex-health minister says: PMLive. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.